Weihong Ding1, Shijun Tong1, Yuancheng Gou1, Chuanyu Sun1, Hong Wang2, Zhongqing Chen2, Jun Tan3, Ke Xu4, Guowei Xia1, Qiang Ding1. 1. Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. 2. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China. 3. Department of Biostatistics and Social Medicine, School of Public Health, Fudan University, Shanghai, 200032, China. 4. Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China. drkexu@163.com.
Abstract
PURPOSE: Current pathological and clinical parameters provide important prognostic information. However, they are still limitations for predicting the true malignant potential of a specific cancer. The aim of this study was to validate the predicting role of HER-2 expression and demonstrated that combination of the high-risk factors with HER-2 expression is more valuable for determining which non-muscle-invasive bladder cancer (NMIBC) is more aggressive. MATERIALS AND METHODS: In total, 238 patients treated by transurethral resection of the bladder tumor were histopathologically confirmed to be NMIBC. Two experienced uropathologists re-reviewed the slides. HER-2 expression was evaluated by immunohistochemistry and scored for intensity and area of staining. The association of HER-2 staining with tumor recurrence and progression was evaluated by univariate and multivariate analyses and Kaplan-Meier survival curves. RESULTS: In multivariable analyses, HER-2 expression was an independent risk factor for predicting tumor progression (HR 2.64, p = 0.024). Combining the EORTC risk scores with HER-2 expression status led to more accurate prediction of progression, especially in patients with intermediate- and high-risk EORTC scores (p < 0.0001, log-rank test). CONCLUSIONS: HER-2 positivity is prognostic for predicting progression to muscle invasion in NMIBC. Combination of the high-risk factors with HER-2 expression is more valuable for determining which NMIBC is more aggressive.
PURPOSE: Current pathological and clinical parameters provide important prognostic information. However, they are still limitations for predicting the true malignant potential of a specific cancer. The aim of this study was to validate the predicting role of HER-2 expression and demonstrated that combination of the high-risk factors with HER-2 expression is more valuable for determining which non-muscle-invasive bladder cancer (NMIBC) is more aggressive. MATERIALS AND METHODS: In total, 238 patients treated by transurethral resection of the bladder tumor were histopathologically confirmed to be NMIBC. Two experienced uropathologists re-reviewed the slides. HER-2 expression was evaluated by immunohistochemistry and scored for intensity and area of staining. The association of HER-2 staining with tumor recurrence and progression was evaluated by univariate and multivariate analyses and Kaplan-Meier survival curves. RESULTS: In multivariable analyses, HER-2 expression was an independent risk factor for predicting tumor progression (HR 2.64, p = 0.024). Combining the EORTC risk scores with HER-2 expression status led to more accurate prediction of progression, especially in patients with intermediate- and high-risk EORTC scores (p < 0.0001, log-rank test). CONCLUSIONS:HER-2 positivity is prognostic for predicting progression to muscle invasion in NMIBC. Combination of the high-risk factors with HER-2 expression is more valuable for determining which NMIBC is more aggressive.
Authors: K Sato; M Moriyama; S Mori; M Saito; T Watanuki; K Terada; E Okuhara; T Akiyama; K Toyoshima; T Yamamoto Journal: Cancer Date: 1992-11-15 Impact factor: 6.860
Authors: Surendra B Kolla; Amlesh Seth; Manoj K Singh; Narmada P Gupta; Ashok K Hemal; Prem N Dogra; Rajeev Kumar Journal: Int Urol Nephrol Date: 2008 Impact factor: 2.370
Authors: Barthold Ph Schrier; Maarten P Hollander; Bas W G van Rhijn; Lambertus A L M Kiemeney; J Alfred Witjes Journal: Eur Urol Date: 2004-03 Impact factor: 20.096
Authors: Francesca Sanguedolce; Antonella Cormio; Paolo Massenio; Maria C Pedicillo; Simona Cagiano; Francesca Fortunato; Beppe Calò; Giuseppe Di Fino; Giuseppe Carrieri; Pantaleo Bufo; Luigi Cormio Journal: J Cancer Res Clin Oncol Date: 2018-01-23 Impact factor: 4.553
Authors: Armin Soave; Lan Kluwe; Hang Yu; Michael Rink; Philipp Gild; Malte W Vetterlein; Philipp Marks; Guido Sauter; Margit Fisch; Christian P Meyer; Tim Ludwig; Roland Dahlem; Sarah Minner; Klaus Pantel; Bettina Steinbach; Heidi Schwarzenbach Journal: Sci Rep Date: 2020-12-09 Impact factor: 4.379